https://erstressinhibitors.com..../genome-resolved-met
© 2020 The Authors. Cancer drug published by John Wiley Sons Ltd.Emergence of clones holding point mutations in the BCR-ABL1 kinase domain (KD) is a very common procedure of resistance to tyrosine kinase inhibitor (TKI)-based therapies in Philadelphia chromosome-positive (Ph+) severe lymphoblastic leukemia (ALL). Sanger sequencing (SS) is considered the most frequently employed way for diagnostic BCR-ABL1 KD mutation tes
Curtir
Comentario
Compartilhar
